MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer
Received: 19 April 2000 Accepted: 05 December 2000 DOI:
Cite this article as: Esserman, L., Kaplan, E., Partridge, S. et al. Ann Surg Oncol (2001) 8: 549. doi:10.1007/s10434-001-0549-8 Abstract Background: The preferred management for women with stage II or locally advanced breast cancer (LABC) is neoadjuvant chemotherapy. Pathologic response to chemotherapy has been shown to be an excellent predictor of outcome. Surrogates that can predict pathologic response and outcome will fuel future changes in management. Magnetic resonance imaging (MRI) demonstrates that patients with LABC have distinct tumor patterns. We investigated whether or not these patterns predict response to therapy. Methods: Thirty-three women who received neoadjuvant doxorubicin and cyclophosphamide chemotherapy for 4 cycles and serial breast MRI scans before and after therapy were evaluated for this study. Response to therapy was measured by change in the longest diameter on the MRI. Results: Five distinct imaging patterns were identified: circumscribed mass, nodular tissue infiltration diffuse tissue infiltration, patchy enhancement, and septal spread. The likelihood of a partial or complete response as measured by change in longest diameter was 77%, 37.5%, 20%, and 25%, respectively. Conclusions: MRI affords three-dimensional characterization of tumors and has revealed distinct patterns of tumor presentation that predict response. A multisite trial is being planned to combine imaging and genetic information in an effort to better understand and predict response and, ultimately, to tailor therapy and direct the use of novel agents. Key Words Magnetic resonance imaging Neoadjuvant chemotherapy Locally advanced breast cancer REFERENCES
Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.
N Engl J Med
1991; 324: 160–8.
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group [see comments]. Lancet 1998; 352: 930–42.
Heywang SH, Hahn D, Schmidt H, et al. MR imaging of the breast using gadolinium-DTPA.
J Comput Assist Tomogr
1986; 10: 199–204.
Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations.
1989; 170: 681–6.
Heywang SH, Wolf A, Pruss E, Hilbertz T, Eiermann W, Permanetter W. MR imaging of the breast with Gd-DTPA: use and limitations.
1989; 171: 95–103.
Revel D, Brasch RC, Paajanen H, et al. Gd-DTPA contrast enhancement and tissue differentiation in MR imaging of experimental breast carcinoma.
1986; 158: 319–23.
Pierce WB, Harms SE, Flamig DP, Griffey RH, Evans WP, Hagans JE. Three-dimensional gadolinium-enhanced MR imaging of the breast: pulse sequence with fat suppression and magnetization transfer contrast. Work in progress.
1991; 181: 757–63.
Stack JP, Redmond OM, Codd MB, Dervan PA, Ennis JT. Breast disease: tissue characterization with Gd-DTPA enhancement profiles.
1990; 174: 491–4.
Harms SE, Flamig DP, Hesley KL, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation.
1993; 187: 493–501.
Orel SG, Schnall MD, LiVolsi VA, Troupin RH. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation.
1994; 190: 485–93.
Gribbestad IS, Nilsen G, Fjosne H, et al. Contrast-enhanced magnetic resonance imaging of the breast.
1992; 31: 833–42.
Flickinger FW, Allison JD, Sherry RM, Wright JC. Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI.
Magn Reson Imaging
1993; 11: 617–20.
Dao TH, Rahmouni A, Campana F, Laurent M, Asselain B, Fourquet A. Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging.
1993; 187: 751–5.
Gilles R, Guinebretiere JM, Shapeero LG, et al. Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients.
1993; 188: 473–8.
Heywang SH, Hilbertz T, Pruss E, et al. [Dynamic contrast medium studies with flash sequences in nuclear magnetic resonance tomography of the breast].
1988; 8: 7–13.
Rubens D, Totterman S, Chacko AK, et al. Gadopentetate dimeglumine-enhanced chemical-shift MR imaging of the breast.
AJR Am J Roentgenol
1991; 157: 267–70.
Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique.
1994; 193: 777–81.
Hulka CA, Smith BL, Sgroi DC, et al. Benign and malignant breast lesions: differentiation with echo-planar MR imaging.
1995; 197: 33–8.
Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.
J Clin Oncol
1999; 17: 110–9.
Abraham DC, Jones RC, Jones SE, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging.
1996; 78: 91–100.
Davis PL, Staiger MJ, Harris KB, et al. Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography.
Breast Cancer Res Treat
1996; 37: 1–9.
Rieber A, Zeitler H, Rosenthal H, et al. MRI of breast cancer: influence of chemotherapy on sensitivity.
Br J Radiol
1997; 70: 452–8.
Gilles R, Guinebretiere JM, Toussaint C, et al. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy.
1994; 191: 633–8.
Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy [see comments].
J Clin Oncol
1999; 17: 460–9.
Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
1999; 230: 72–8.
Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
Am J Surg
1998; 176: 502–9.
Kuerer HM, Newman LA, Fornage BD, et al. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer [see comments].
Ann Surg Oncol
1998; 5: 673–80.
Kuerer HM, Newman LA, Buzdar AU, et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status [see comments].
Cancer J Sci Am
1998; 4: 230–6.
Pierga JY. Prognostic value of node involvement after preoperative chemotherapy in 507 patients with operable breast cancer,
Proceedings of ASCO, 1998. Vol. 17.
Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994; 73: 362–9.
James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement [see comments].
J Natl Cancer Inst
1999; 91: 523–8.
Venables WN, Ripley BD. Modern Applied Statistics with S-Plus. Vol. 2. New York: Springer-Verlag, 1997: 247–266.
Esserman L, Kaplan E, Sudilovsky D, Miller J, Hylton N. MRI can predict breast conservation in patients undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat 2000; 64: 116.
Weiss RB, Rifkin RM, Stewart FM, et al. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study.
2000; 355: 999–1003.
Stadtmauer EA, O’Neill A, Goldstein LJ. Phase III randomized trial of high-dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared with maintenance chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the “Ph iladelphia Intergroup Study (PBT-1).
Proc ASCO 1999; 18: 1A(abstr 1).
Peters WP, Rosner G, Vredenburgh J. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG9114/NCIC MA-13.
Proc ASCO 1999; 18: 1(abstr 2).
Esserman L, Hylton N, George T, Weidner N. Contrast-enhanced magnetic resonance imaging to assess tumor histopathology and angiogenesis in breast carcinoma.
1999; 5: 13–21.
PubMed Copyright information
© The Society of Surgical Oncology, Inc. 2001